EYEPOINT PHARMACEUTICALS INC (EYPT)
US30233G2093 - Common Stock
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Which stocks are moving on Monday?
Top movers in Monday's session
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Monday Sector Laggards: Food, Drugs
Gapping stocks in Monday's session
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Top movers in Monday's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate...
Noteworthy Friday Option Activity: IAC, BYON, EYPT
EYPT Crosses Below Key Moving Average Level
Commit To Purchase EyePoint Pharmaceuticals At $12.50, Earn 61% Annualized Using Options
EyePoint Pharmaceuticals is Now Oversold (EYPT)
Noteworthy Thursday Option Activity: GPC, SNPS, EYPT
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D....
Noteworthy Thursday Option Activity: CWCO, EYPT, FDX
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
EyePoint Pharmaceuticals Becomes Oversold (EYPT)
EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
EYPT stock results show that EyePoint Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips EyePoint Pharmaceuticals (NASDAQ:EYPT) just reported results for the fourth qua...
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints;...
Notable Wednesday Option Activity: DKS, PZZA, EYPT
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR – – Initiation...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
The 3 Most Promising Stocks to Invest in Before They Take Off
Sponsored by potential FED interest rate cuts, these are the top stocks to invest in before they take off later this year.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
Notable Wednesday Option Activity: CYRX, HLF, EYPT
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2...
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
JP Morgan starts EyePoint at overweight, cites eye drug potential (NASDAQ:EYPT)
JP Morgan has initiated coverage of EyePoint Pharmaceuticals (EYPT) with an overweight rating, citing the potential of its eye drug EYP-1901. The investment ban